TOP1 and melanoma: Finally, we assessed therapeutic potential of TOP1 inhibitor for targeting WRN‐deficient melanoma tumor, which otherwise is known to be resistant to other therapeutic modalities (Figure 6d,e) (Gupta et al., 2021).